Medic Life Sciences

Founded in 2018, Medic Life Sciences is a private, pre-clinical stage biotech developing a transformative platform for oncology target and biomarker discovery. The company's core innovation integrates CRISPR screening with sophisticated 3D tumor models that include immune cells, aiming to assess the functional impact of cancer mutations on tumor growth, drug response, and immune evasion with high translatability. This approach is designed to address critical failures in the current drug development paradigm by systematically pinpointing the genetic determinants of therapy success, thereby de-risking and accelerating the creation of more effective, targeted cancer treatments. MEDiC appears to be in a platform-building and validation phase, assembling a team and advancing its proprietary technology.

Proprietary platform integrating CRISPR functional genomics with patient-derived 3D tumor-immune co-culture models to systematically identify biomarkers, synthetic lethality, resistance mutations, and novel drug targets.

MEDiC operates in a competitive field of functional genomics and CRISPR screening platforms in oncology. Differentiators include its specific focus on 3D tumor-immune co-culture models for enhanced translatability. It competes with both internal efforts at large pharmaceutical companies and other biotech platforms utilizing organoids, in vivo screens, or different model systems.